COVID-19 in teriflunomide-treated patients with multiple sclerosis

Amir Hadi Maghzi; Maria K. Houtchens; Paolo Preziosa; Carolina Ionete; Biljana Beretich; James Stankiewicz; Shahamat Tauhid; Ann Cabot; Idanis Berriosmorales; Tamara Schwartz; Jacob A. Sloane; Mark S. Freedman; Massimo Filippi; Howard L. Weiner; Rohit Bakshi

doi:10.1007/s00415-020-09944-8

Related publications

Preprint2020

COVID-19 in Teriflunomide-Treated Patients with Multiple Sclerosis

Amir‐Hadi Maghzi, Maria K. Houtchens, Paolo Preziosa, Carolina Ionete, Biljana Beretich, James Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara HW Schwartz, Jacob A. Sloane, Mark S. Freedman, Massimo Filippi, Howard L. Weiner, Rohit Bakshi

Article2021

Cases of COVID-19 in Teriflunomide-Treated Patients With MS: Pharmacovigilance Report (1525)

Céline Louapre, José Manuel García‐Domínguez, Lucia Moiola, Massimo Filippi, Carlo Tornatore, Janneke van Wingerden, Myriam Bénamor

Article2020

COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience

Paolo Preziosa, Maria A. Rocca, Agostino Nozzolillo, Lucia Moiola, Massimo Filippi

Article2022

Signs and symptoms of COVID‐19 in patients with multiple sclerosis

Irene Schiavetti, Luca Carmisciano, Marta Ponzano, Cinzia Cordioli, Eleonora Cocco, Girolama Alessandra Marfia, Matilde Inglese, Massimo Filippi, Marta Radaelli, Roberto Bergamaschi, Paolo Immovilli, Marco Capobianco, Nicola De Rossi, Giampaolo Brichetto, Cinzia Scandellari, Paola Cavalla, Ilaria Pesci, Paolo Confalonieri, Paola Perini, María Trojano, Roberta Lanzillo, Gioacchino Tedeschi, Gıancarlo Comı, Mario Alberto Battaglia,

Letter2021

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?

Stefano Gelibter, Mario Orrico, Massimo Filippi, Lucia Moiola